Syriopoulou Vassiliki, Daikos George L, Theodoridou Maria, Pavlopoulou Ioanna, Manolaki Archondia G, Sereti Evagelia, Karamboula Aikaterini, Papathanasiou Dimitra, Krikos Xenophon, Saroglou George
First Department of Pediatrics, Aghia Sophia Children's Hospital, Athens 11527, Greece.
Clin Infect Dis. 2003 Mar 1;36(5):560-6. doi: 10.1086/367843. Epub 2003 Feb 17.
To evaluate the efficacy of a short course of a lipid formulation of amphotericin B (L-AmB) for the treatment of Mediterranean visceral leishmaniasis (VL), an open prospective study was conducted. Forty-one children with parasitologically confirmed leishmaniasis received L-AmB, 10 mg/kg daily for 2 days. The comparison groups were 30 children who, in a previous study, were treated with L-AmB, 4 mg/kg daily for 5 days, and 52 children who were treated with meglumine antimoniate. At 6 months after completion of treatment, overall treatment success was noted for 40 of 41 children treated with 2 doses of L-AmB, 27 of 30 children treated with 5 doses of L-AmB, and 47 of 52 children treated with meglumine antimoniate. Abatement of fever, reduction in spleen size, and correction of laboratory parameters occurred more quickly among the children who received 2 doses of L-AmB than among the comparison groups, and the total estimated cost of the 2-dose regimen was also lower than that of the other regimens. Two doses of L-AmB, 10 mg/kg each, is cost-effective therapy for Mediterranean VL in children.
为评估脂质体两性霉素B（L-AmB）短疗程治疗地中海内脏利什曼病（VL）的疗效，开展了一项开放性前瞻性研究。41例经寄生虫学确诊的利什曼病患儿接受L-AmB治疗，每日10mg/kg，共2天。对照组为30例患儿，在先前研究中接受每日4mg/kg、共5天的L-AmB治疗，以及52例接受葡甲胺锑酸盐治疗的患儿。治疗结束6个月时，41例接受2剂L-AmB治疗的患儿中有40例总体治疗成功，30例接受5剂L-AmB治疗的患儿中有27例，52例接受葡甲胺锑酸盐治疗的患儿中有47例。接受2剂L-AmB治疗的患儿发热消退、脾脏缩小及实验室指标恢复正常的速度比对照组更快，且2剂治疗方案的总估计费用也低于其他方案。两剂L-AmB，每次10mg/kg，是治疗儿童地中海VL的具有成本效益的疗法。
